New Report Covers Acute Myelocytic Leukemia - Pipeline Review, H2 2016

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

Complete report available @ Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 91, 90, 1, 6, 143, 22 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 14, 24 and 10 molecules, respectively.

Acute Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4SC AG AB Science SA AbbVie Inc Acetylon Pharmaceuticals Inc Actinium Pharmaceuticals Inc ADC Therapeutics Sarl Advenchen Laboratories LLC Aeglea BioTherapeutics Inc Affichem SA Agios Pharmaceuticals Inc Aileron Therapeutics Inc AIMM Therapeutics BV Akinion Pharmaceuticals AB Alexion Pharmaceuticals Inc Altor BioScience Corp Amgen Inc Antigen Express Inc Antisense Therapeutics Ltd APIM Therapeutics AS Aprea AB arGEN-X BV Ariad Pharmaceuticals Inc Arno Therapeutics Inc Arog Pharmaceuticals Inc Array BioPharma Inc Astellas Pharma Inc Asterias Biotherapeutics Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Athenex Inc Aurigene Discovery Technologies Ltd AVEO Pharmaceuticals Inc Bayer AG BCI Pharma Bellicum Pharmaceuticals Inc BerGenBio AS Bio-Cancer Treatment International Ltd Bio-Path Holdings Inc BioInvent International AB BioLineRx Ltd BioSight Ltd Blueprint Medicines Corp Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc Cancer Therapeutics CRC Pty Ltd Cantargia AB Cantex Pharmaceuticals Inc Cascadian Therapeutics Inc Celgene Corp Cellceutix Corp Celldex Therapeutics Inc Cellectar Biosciences Inc Cellectis SA Cellerant Therapeutics Inc Celyad SA CharlestonPharma LLC Cielo Therapeutics Inc Constellation Pharmaceuticals Inc Cornerstone Pharmaceuticals Inc Critical Outcome Technologies Inc CrystalGenomics Inc CSPC Pharmaceutical Group Limited CTI BioPharma Corp Cyclacel Pharmaceuticals Inc Daiichi Sankyo Company Ltd DC Prime BV Deciphera Pharmaceuticals LLC DiNonA Inc Eisai Co Ltd Eli Lilly and Company Emercell SAS EntreChem SL EpiZyme Inc Erytech Pharma SA Esperance Pharmaceuticals Inc Exelixis Inc F. Hoffmann-La Roche Ltd Fate Therapeutics Inc FLX Bio Inc FORMA Therapeutics Inc Formula Pharmaceuticals Inc Fortress Biotech Inc Fujifilm Corp Gadeta BV Gamida Cell Ltd Genentech Inc Genoscience Pharma Genosco Inc Genzyme Corp Gilead Sciences Inc GlaxoSmithKline Plc GlycoMimetics Inc Golden Biotechnology Corp H3 Biomedicine Inc Hanmi Pharmaceuticals Co Ltd HEC Pharm Co Ltd Hybrigenics SA Igenica Biotherapeutics Inc Ignyta Inc Immatics Biotechnologies GmbH Immune Pharmaceuticals Inc Immune System Key Ltd ImmunGene Inc ImmunoGen Inc Immunomedics Inc Incyte Corp Inflection Biosciences Ltd Interprotein Corp Io Therapeutics Inc IPD Therapeutics BV Jasco Pharmaceuticals LLC Jazz Pharmaceuticals Plc Jeil Pharmaceutical Co Ltd Johnson & Johnson Juno Therapeutics Inc JW Pharmaceutical Corp Kainos Medicine Inc Karyopharm Therapeutics Inc Kiadis Pharma NV Kite Pharma Inc Komipharm International Co Ltd Kyowa Hakko Kirin Co Ltd Lead Discovery Center GmbH Les Laboratoires Servier SAS MacroGenics Inc Mateon Therapeutics Inc MaxCyte Inc medac GmbH MediGene AG Medivation Inc MEI Pharma Inc Merck & Co Inc Merck KGaA Merus NV Mesoblast Ltd Millennium Pharmaceuticals Inc miRagen Therapeutics Inc Moleculin Biotech Inc MolMed SpA Nanovalent Pharmaceuticals Inc NantKwest Inc Nemucore Medical Innovations Inc Nerviano Medical Sciences Srl Neumedicines Inc NewLink Genetics Corp Novartis AG NuCana BioMed Ltd Omeros Corp OncoImmune Inc Onconova Therapeutics Inc Oncopeptides AB OncoTartis Inc OncoTherapy Science Inc Oncternal Therapeutics Inc Ono Pharmaceutical Co Ltd Otsuka Holdings Co Ltd Oxford BioTherapeutics Ltd Panther Biotechnology Inc Petra Pharma Corp Pfizer Inc Pharma Mar SA Pharmascience Inc Pharmedartis GmbH Philogen SpA Phylogica Ltd Polaris Pharmaceuticals Inc ProNAi Therapeutics Inc Resverlogix Corp Rich Pharmaceuticals Inc Sanofi Sareum Holdings Plc Seattle Genetics Inc Sellas Inc Selvita SA Senhwa Biosciences Inc Shire Plc SialoTec GmbH Sigma-Tau SpA SOM Biotech SL Sorrento Therapeutics Inc Stemline Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Sunesis Pharmaceuticals Inc Syndax Pharmaceuticals Inc SYNIMMUNE GmbH Syros Pharmaceuticals Inc TaiGen Biotechnology Co Ltd Taiho Pharmaceutical Co Ltd Takara Bio Inc Takeda Pharmaceutical Company Ltd Targazyme Inc TetraLogic Pharmaceuticals Teva Pharmaceutical Industries Ltd Theravectys SA Toko Pharmaceutical Industries Co Ltd Tolero Pharmaceuticals Inc Tragara Pharmaceuticals Inc Trillium Therapeutics Inc Vichem Chemie Research Ltd VioQuest Pharmaceuticals Inc Viralytics Ltd Vyriad Inc Xencor Inc Xenetic Biosciences (UK) Ltd Zenith Capital Corp ZIOPHARM Oncology Inc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###